iShares Biotechnology ETF
883 hedge funds and large institutions have $5.15B invested in iShares Biotechnology ETF in 2024 Q3 according to their latest regulatory filings, with 79 funds opening new positions, 242 increasing their positions, 315 reducing their positions, and 74 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
883
Holders Change
-4
Holders Change %
-0.45%
% of All Funds
12.77%
Holding in Top 10
10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-9.09%
% of All Funds
0.14%
New
79
Increased
242
Reduced
315
Closed
74
Calls
$496M
Puts
$810M
Net Calls
-$314M
Net Calls Change
+$658M
Top Buyers
| 1 |
1
BNP Paribas Financial Markets
Paris,
France
|
$347M |
| 2 |
2
Jane Street
New York
|
$209M |
| 3 |
3
Morgan Stanley
New York
|
$460M |
| 4 |
4
BlackRock
New York
|
$57.6M |
| 5 |
5
Barclays
London,
United Kingdom
|
$52M |
Top Sellers
| 1 |
1
Goldman Sachs
New York
|
$199M |
| 2 |
2
JPMorgan Chase & Co
New York
|
$83.1M |
| 3 |
3
Citigroup
New York
|
$288M |
| 4 |
4
Bank of America
Charlotte,
North Carolina
|
$1.04B |
| 5 |
JHU
5
Johns Hopkins University
Baltimore,
Maryland
|
$0 |